Calvin Ho to Humans
This is a "connection" page, showing publications Calvin Ho has written about Humans.
Connection Strength
0.427
-
Patient experience with eosinophilic esophagitis symptoms and impacts on daily life based on in-trial qualitative interviews. J Patient Rep Outcomes. 2025 Jan 08; 9(1):3.
Score: 0.093
-
Assessing usability of electronic patient-reported outcome measures in older people with and without a rare dermatologic disorder. J Patient Rep Outcomes. 2024 Dec 18; 8(1):145.
Score: 0.093
-
Development and content validation of a symptom assessment for eosinophilic gastritis and eosinophilic gastroenteritis in adults and adolescents. Orphanet J Rare Dis. 2021 11 24; 16(1):495.
Score: 0.075
-
Benralizumab versus placebo for hypereosinophilic syndrome: a randomized, placebo-controlled phase 3 trial. Nat Med. 2026 Jun; 32(6):2017-2025.
Score: 0.025
-
Multi-stakeholder use of patient experience data (PED): current state and future opportunities for the application of PED to inform decision-making. J Patient Rep Outcomes. 2026 Mar 24; 10(1).
Score: 0.025
-
The role of patient-reported outcomes in health technology assessments: global practices and future implications. Expert Rev Pharmacoecon Outcomes Res. 2026 Feb; 26(2):211-219.
Score: 0.025
-
Two-year efficacy and safety of anti-interleukin-5/receptor therapy for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis. 2025 Nov; 84(11):1888-1899.
Score: 0.024
-
Benralizumab does not elicit therapeutic effect in patients?with chronic spontaneous urticaria: results from the phase IIb multinational randomized double-blind placebo-controlled ARROYO trial. Br J Dermatol. 2024 Jul 16; 191(2):187-199.
Score: 0.022
-
Eosinophil Depletion with Benralizumab for Eosinophilic Esophagitis. N Engl J Med. 2024 Jun 27; 390(24):2252-2263.
Score: 0.022
-
Treating moderate-to-severe atopic dermatitis with benralizumab: results from the HILLIER study, a plain language summary. Immunotherapy. 2024; 16(10):641-648.
Score: 0.022